Abstract | PURPOSE: THE AIM: of this review is to recall the rationale of use of IL-1Ra and to analyse the results available in the current literature. CURRENT KNOWLEDGE AND KEY POINTS: Pathophysiological data of RA give a specific position for IL-1 as a potential target for immunotherapy in this disease, confirmed in animal models. Phase II and III studies with IL-1Ra ( Anakinra) demonstrated clinical efficacy versus placebo (42% responders in ACR 20 in Anakinra + methotrexate, and 23% in the placebo + methotrexate group at 24 weeks) and a structural effect (slowing of radiological progression at six months). Anakinra has obtained an European license and is indicated in RA not controlled by methotrexate, in daily subcutaneous administration (100 mg/day), in combination with methotrexate. Tolerance is fair; the most frequent side effect is represented by injection site reactions. FUTURE PROSPECTS AND PROJECTS: This ambulatory biotherapy offers new perspectives in combination with other slow acting drugs as well as biologic agents such as anti-TNF, currently under evaluation.
|
Authors | D Wendling, C Jorgensen |
Journal | La Revue de medecine interne
(Rev Med Interne)
Vol. 23
Issue 12
Pg. 1006-11
(Dec 2002)
ISSN: 0248-8663 [Print] France |
Vernacular Title | Traitement de la polyarthrite rhumatoïde par l'antagoniste du récepteur de l'interleukine 1. |
PMID | 12504237
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- IL1RN protein, human
- Interleukin 1 Receptor Antagonist Protein
- Receptors, Interleukin-1
- Sialoglycoproteins
|
Topics |
- Animals
- Arthritis, Rheumatoid
(drug therapy)
- Clinical Trials as Topic
- Disease Models, Animal
- Drug Therapy, Combination
- Humans
- Interleukin 1 Receptor Antagonist Protein
- Receptors, Interleukin-1
(antagonists & inhibitors)
- Sialoglycoproteins
(therapeutic use)
|